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ABSTRACT
Objective: Would there be any difference in the prognosis 
for patients who presented, for example, 8% or 88% 
tumor necrosis induced by chemotherapy, even though 
both individuals were considered to be poor responders? 
The aim of this study was to compare the prognoses 
for different histological grades (Huvos grade I versus 
grade II), consequent to chemotherapy, among patients 
with primary osteosarcoma that was not metastatic at 
diagnosis.  Methods: Twenty-four patients admitted to 
a referral center between 2000 and 2004 were selected 
for the study. The accumulated chances of survival were 
calculated using the Kaplan-Meier technique. Huvos 
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INTRODUCTION
Osteosarcoma is an aggressive malignant 
type of neoplasia of mesenchymal origin that is 
characterized by irregular formation of immature 
bone and production of osteoid matrix and 
malignant stromal fusiform cells(1). It is one of the 
commonest types of primary non-hematopoietic 
bone sarcoma(2-4), albeit uncommon if compared 
with neoplasia in general(2).
In the United States, the annual incidence of 
osteosarcoma is 6.5 patients per million children, or 
900 new cases per year(5). In Brazil, the real incidence 
is difficult to determine because of the lack of adequate 
grades I and II for necrosis consequent to chemotherapy 
were evaluated as variables in order to determine their 
prognostic value, in relation to local recurrence-free 
survival, metastasis-free survival and overall survival, 
using the log-rank test. Results: Comparing Huvos grades 
I and II, the following P values for survival were attained: 
local recurrence-free survival (P = 0.731), metastasis-free 
survival (P = 0.596) and overall survival (P = 0.669). 
Conclusion: In this series, Huvos grades I and II did 
not have any comparative prognostic value and had
similar behavior.
Keywords – Bone Neoplasms/pathology; Drug Therapy; 
Prognosis; Survivors
records. However, it has been estimated that there are 
350 new cases per year(6).
The appropriate treatment for high-grade malignant 
osteosarcoma consists of a multidisciplinary approach 
based on preoperative chemotherapy (neoadjuvant), 
surgery and postoperative chemotherapy (adjuvant). 
A recent multi-institutional retrospective study(7) sug-
gested that a combination of surgery and chemothera-
py seems to be the standard choice of treatment and, 
likewise, chemotherapy may function better if used 
both preoperatively and postoperatively. 
The prognosis for patients with osteosarcoma has 
improved considerably over recent decades. This has 
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underwent treatment for osteosarcoma. The following 
inclusion criteria were used: (a) Anatomopathological 
confirmation of primary osteosarcoma: all the slides 
were reviewed by a pathologist who was a specialist 
on musculoskeletal tissues; (b) Patients who were all 
treated (during the study period) using the same proto-
col for neoadjuvant chemotherapy (Study V, GBTO); 
(c) Patients who underwent operations at our clinic for 
local control of the primary tumor after the chemo-
therapy; (d) Patients who were considered to be poor 
responders to the preoperative chemotherapy that was 
instituted (grades I and II according to the classifica-
tion of Huvos et al(22). The following exclusion cri-
teria were used: (a) Presence of pulmonary or bone 
metastases at the initial assessment; (b) Presence of 
tumors with low-grade malignity; (c) Patients who did 
not undergo neoadjuvant chemotherapy or who died 
during this therapy; (d) Patients who had undergone 
some form of treatment for the tumor prior to regis-
tration at our clinic. The anatomopathological review 
was conducted using paraffin blocks containing tumor 
fragments from the surgical specimen, in all the cases.
This protocol was approved by our institution’s 
research ethics committee.
STATISTICAL ANALYSIS
The study database was compiled in a spreadsheet 
within the Excel 2007 software for Windows, after 
applying a protocol to the medical files. The statistical 
analyses were performed using the SPSS statistical 
software, version 12.0 (SPSS Inc., Chicago, IL, USA).
The accumulated survival probabilities were calcu-
lated by means of the Kaplan-Meier technique. Huvos 
grades I and II, for the degree of necrosis after the 
effect of the chemotherapy, were evaluated as varia-
bles to determine their prognostic value in relation to 
survival free from local recurrence, survival free from 
metastasis and overall survival, using the Log-Rank 
test. Statistical significance was defined as p < 0.05.
RESULTS
In the sample of 24 cases, the histological respon-
ses to preoperative chemotherapy according to the 
criteria of Huvos et al. (1977) comprised 18 cases 
(75.0%) with grade I and six cases (25.0%) with grade 
II (Figure 1). The mean length of follow-up among 
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occurred through adequate staging of these tumors, 
improved imaging methods and, especially, polyche-
motherapy. Today, the five-year disease-free survival 
rate has reached 60-70%, using the most recent che-
motherapy protocols(8-12).
Poor histological response to preoperative chemo-
therapy, as assessed by the degree of necrosis in the 
surgical specimen, is also considered to be one of the 
most important unfavorable prognostic factors rela-
ting to the survival of osteosarcoma patients(6,7,8,13-21). 
In the literature, the grading method that is still most 
used is the one described by Huvos et al(22), in 1977. 
In this, these authors divided the degree of necrosis 
into four types: grade I, no effect from chemotherapy; 
grade II, partial response with more than 50% necro-
sis; grade III, more than 90% necrosis, with a viable 
tumor present; or grade IV, without a viable tumor. 
According to Rosen et al(23), patients are considered to 
be, respectively, good or poor responders if they pre-
sent tumor necrosis in the resected specimen greater 
than or less than 90%. Based on these classifications, 
the question that we pose is the following: Would 
there be a difference in prognosis between patients 
who presented, for example, 8 or 88% tumor necrosis 
induced by chemotherapy, even though both of these 
cases would be considered to be poor responders?
The aim of the present study was to compare the 
prognosis for the histological grading (Huvos grade 
I versus grade II) after the effect of chemotherapy, 
among patients with primary osteosarcoma that was 
not metastatic at the time of diagnosis, with treatment 
in accordance with Study V of the Brazilian Coope-
rative Group for Osteosarcoma Treatment (GBTO).
SAMPLE AND METHODS
The medical files of patients with an anatomopa-
thological diagnosis of primary osteosarcoma made 
by the orthopedic oncology group of a referral clinic 
between 2000 and 2004 were analyzed. These patients 
were treated in accordance with Study V of the Brazi-
lian Cooperative Group for Osteosarcoma Treatment 
(GBTO), with cisplatin (120 mg/m2/cycle), ifosfami-
de (13.5 mg/m2/cycle) and Adriamycin® (80 mg/m2/
cycle), totaling nine cycles for patients who were non-
-metastatic at diagnosis. The analysis on the variable 
was performed on 24 medical files of patients who 
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the patients with non-metastatic osteosarcoma in our 
sample was 39.08 months (with a standard deviation 
of 28.16 months and median of 47 months), ranging 
from two to 83 months. 
The prognostic values of the degrees of tumor ne-
crosis after chemotherapy were evaluated based on 
the local recurrence-free survival (LRFS), metastasis-
-free survival (MFS) and overall survival (OS) curves. 
The degrees of tissue necrosis after chemotherapy 
(Huvos I versus Huvos II) did not reach statistically 
significant levels and were not considered to be prog-
nostic factors for LRFS (Figure 2).
Figure 1 – Macroscopic preparation of a surgical specimen 
together with its radiograph, ready for microscopic analysis 
(histopathology) on tumor after chemotherapy.
Figure 2 – Local recurrence-free survival curve in months for 
the 24 patients with primary non-metastatic osteosarcoma at 
diagnosis, according to the degree of tumor necrosis after the 
effect of chemotherapy (Huvos I and II).
Figure 3 - Metastasis-free survival curve in months for the 24 
patients with primary non-metastatic osteosarcoma at diagnosis, 
according to the degree of tumor necrosis after the effect of 
chemotherapy (Huvos I and II).
Figure 4 - Overall survival curve in months for the 24 patients with 
primary non-metastatic osteosarcoma at diagnosis, according to 
the degree of tumor necrosis after the effect of chemotherapy 
(Huvos I and II).
DISCUSSION 
Despite the relative rarity of osteosarcoma, several 
studies(7,12,15-17,20,21,24-27),  including some within our 
setting, have sought to identify risk factors that might 
influence the natural history of this tumor and the 
prognosis for patients. 
The efficacy of chemotherapy and its impact on 
the survival of patients with osteosarcoma are well 
documented(6,7). There seems to be almost a consensus 
in the literature(7,8,12,13,17-19) that the degree of tumor 
necrosis induced by preoperative chemotherapy is an 
important prognostic factor in relation to the survi-
val of patients with primary osteosarcoma. This has 
also been seen in Brazilian studies(6,15,21,24,25). Patients 
whose resected surgical specimens present tumor ne-
crosis greater than 90% (Huvos types III and IV) have 
a better prognosis than shown by those whose speci-
mens present tumor necrosis of less than 90% (Huvos 
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Comparing the degrees of tumor necrosis (Huvos I 
versus Huvos II), they did not reach statistically signi-
ficant levels and were not considered to be prognostic 
factors for MFS (Figure 3).
The anatomopathological grading (Huvos I versus 
Huvos II) also did not influence OS (Figure 4).
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types I and II). Thus, we compared the poor respon-
ders (< 90% tumor necrosis): Huvos type I (< 50%) 
versus type II (50 to 90%), in relation to the survival 
parameters (LRFS, MFS and OS), and observed that 
these are not adverse factors. 
In this study, stratification into groups I and II, 
following the Huvos criteria, was not shown to be 
necessary, given the similar behavior presented by 
the two groups, in the statistical analysis. These sta-
tistical results suggest that groups I and II presented 
homogenous behavior, including in relation to the 
therapeutic responses made, thus confirming a trend 
in the worldwide literature, in which the cutoff point 
is 90% in the histological analysis.
A preliminary evaluation of this study seems to 
demonstrate that patients with tumor necrosis of Hu-
vos grades I and II after neoadjuvant chemotherapy 
have similar prognostic behavior, despite the wide 
difference in percentage range in these two groups 
when summed (0 to 90%). However, further studies 
are needed in order to establish a comparative analysis 
between Huvos groups I and II and thereby corrobo-
rate the above affirmation.
CONCLUSION 
In this series, comparison between Huvos grades I 
and II showed that they did not have any prognostic va-
lue in relation to any of the survival parameters studied 
(LRFS, MFS and OS), since they behaved similarly.
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